Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis

Sáinz de la Cuesta R, Ricardo Sáinz de la Cuesta, Izquierdo M, Manuel Izquierdo, Cañamero M, Marta Cañamero, Granizo JJ, Juan José Granizo, Manzarbeitia F, Felix Manzarbeitia, Félix Manzarbeitia
European journal of obstetrics, gynecology, and reproductive biology · 2003 · vol. 113(1) , pp. 87–93 · doi:10.1016/s0301-2115(03)00367-1 · PMID:15036718 · W2057436775
article OA: closed CC0 ⤵ 68 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This study investigated the prevalence of p53 overexpression, finding it increases from typical endometriosis to atypical endometriosis and subsequently to ovarian cancer associated with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo evaluate the expression of p53, c-erb-B-2, MIB1 and Bcl-2 in normal endometrium, endometriosis, atypical endometriosis and ovarian cancer associated with endometriosis, looking for immunohistochemical markers that may help determine endometriosis with premalignant potential.Study designBetween 1948 and 1999, 410 epithelial ovarian cancers and 521 cases of endometriosis were surgically treated at Fundación Jiménez Díaz. Pathology reports and slides were reviewed. Four groups were defined: (1) endometriosis/cancer (n=17); (2) atypical endometriosis (n=6); (3) endometriosis (n=17); (4) endometrium (n=7). Tumors and controls were immunostained and evaluated for expression of p53, c-erb-B-2, MIB1 and Bcl-2. Statistical analysis was performed using Chi-square for linear trends, Fisher exact and Kruskal-Wallis tests.ResultsOf the 410 cancers, 17 (4.1%) had associated endometriosis and of the 521 endometriosis, 6 (1.2 %) had atypical changes. Fourteen of 17 (82.4%) cancers associated with endometriosis and all atypical endometriosis had p53 overexpression. Only 2 of 17 (11.8%) endometriosis and none of the endometriums had mutant p53 (P<0.01). We found a trend towards increased expression of MIB1 (0.073) in the cancer and atypical endometriosis groups, and no differences in expression of Bcl-2 or c-erb-B-2. The sensitivity and specificity of p53 as a marker for the diagnosis of atypical endometriosis and cancer associated with endometriosis were 87%; CI 95% (73.2-100%) and 92% (80.6-100%), respectively. When comparing all groups, the mean positive p53 and MIB1 cell count was statistically significant (P=0.01).ConclusionsOverexpression of p53 in atypical endometriosis and cancer associated with endometriosis is a common finding and may be used to identify endometriosis with premalignant potential.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Biomarkers, Tumor Endometriosis Genes, p53 Ovarian Neoplasms Adult Aged Biomarkers, Tumor Endometriosis Endometriosis Female Gene Expression Regulation, Neoplastic Genes, erbB-2 Genes, erbB-2 Genes, p53 Humans Ki-67 Antigen Ki-67 Antigen Middle Aged Ovarian Neoplasms Ovarian Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (23)

Cited by (50)

Source provenance

europepmc
last seen: 2026-08-06T06:07:45.168820+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:38.158000+00:00
License: CC0 · commercial use OK